Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Bewegingsintensiteit en postprandiale effecten van het doorbreken van sedentair gedrag bij volwassenen met overgewicht

21 september 2026 bijgewerkt door: Muhammed Mustafa Atakan, Hacettepe University

Postprandiale Cardiometabole Effecten van het Onderbreken van Zittend Gedrag met Beweging van Variërende Intensiteit bij Gezonde Volwassenen met Overgewicht

The purpose of this study is twofold: (1) to determine whether breaking up prolonged sitting with aerobic or sprint cycling breaks reduces postprandial blood glucose, insulin, CRP, and blood pressure, which are established risk markers for cardiometabolic diseases; and (2) to assess substrate oxidation during this period in order to identify which exercise condition promotes the greatest increase in fat oxidation.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Sedentary behavior (SED) refers to activities such as sitting, lying down, or reclining that require energy expenditure of ≤1.5 MET during the time spent awake. Prolonged and continuous sedentary behavior leads to adverse effects such as abnormal postprandial metabolic responses, insulin resistance, vascular dysfunction, high blood pressure, increased carbohydrate oxidation, and inflammation. Epidemiological data also show that SED increases the risk of mortality, cardiovascular disease, type 2 diabetes, and certain types of cancer. Experimental studies have shown that 2-5 minutes of low- or moderate-intensity aerobic exercise performed every 20-30 minutes during the postprandial period improves cardiometabolic health by reducing glucose, insulin, and blood pressure during the postprandial period. On the other hand, it is known that short-term sprint interval exercise (SIE) increases insulin sensitivity by rapidly depleting muscle glycogen, improves glucose control, lowers blood pressure, and increases fat oxidation. With these effects, SIE may be a time-efficient method for interrupting SED. Although the cardiometabolic benefits of SIE and aerobic exercise interruptions (AEI) are known, there is a lack of studies comparing the effects of interrupting SED with these two exercise types of different intensities in preventing postprandial cardiometabolic dysfunction. In this context, the aim of the study is to compare the postprandial cardiometabolic effects of interrupting sedentary behavior with AIE and sprint exercise interruptions (SEI) in overweight but otherwise healthy women and men aged 30-45. In this randomized crossover trial, volunteers will participate in three trials: 1) AEI, 2) SEI, and 3) SED. There will be a minimum 4-day washout period between trials. In the SEI and AEI trials, exercise interruptions will be implemented every 30 minutes during the 7-hour sitting period, whereas in the SED trial, participants will remain seated continuously for the entire duration. In all conditions, two meals (breakfast and lunch) will be served 3 hours apart, and the trials will begin, after the breakfast meal is consumed. Venous blood samples for every 30 minutes of the first two hours following meals to measure glucose and to be taken hourly during the rest experiment will be used to analyze insulin, glucose, and C-reactive protein (CRP) levels. In addition, blood pressure will be measured hourly, and fat oxidation will be assessed at the baseline, 2nd, 5th, and 7th hours. The effects of the conditions on glucose and insulin will be evaluated using linear mixed models. A Two-Way (Trial x Number of Repeats) Analysis of Variance for Repeated Measures will be used to detect differences between conditions.

Studietype

Ingrijpend

Inschrijving (Geschat)

18

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Turkije (Türkiye)
    • Beytepe
      • Ankara, Beytepe, Turkije (Türkiye)
        • Werving
        • Hacettepe Sports Science Faculty, Hacettepe Beytepe Clinic
        • Contact:
        • Hoofdonderzoeker:
          • Hikmet Sercan Toprakoğlu
        • Onderonderzoeker:
          • Seda Hanife Oğuz Baykal, Associate Professor
        • Onderonderzoeker:
          • Muhammed Mustafa Atakan, Associate Professor
        • Onderonderzoeker:
          • Yasemin Güzel, Doctoral faculty member
        • Onderonderzoeker:
          • Yiğitcan Karanfil, Doctoral faculty member
        • Onderonderzoeker:
          • İbrahim Türkel, Doctoral faculty member
        • Onderonderzoeker:
          • Şükran Nazan Koşar, Professor

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

30 jaar tot 45 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria

  • Being physically inactive (not doing at least 150 minutes/week of structured exercise).
  • Being sedentary (having a daily sedentary time/day for >7 hours).
  • Having a BMI between 25 and 29.9 kg/m2.
  • Having a history of regular menstrual cycles for female participants.
  • Having medical examination approval.

Exclusion Criteria

  • Taking any acute or chronic medication or supplement that may affect metabolism.
  • Having an acute or chronic illness that limits exercise (musculoskeletal problems, cardiovascular disorders, respiratory problems, etc.).
  • Consuming tobacco products.
  • Meeting 3 or more of the metabolic syndrome criteria (waist circumference of 102 cm or more in men, 88 cm or more in women, triglyceride level of 150 mg/dL or higher, HDL cholesterol level below 40 mg/dL in men and 50 mg/dL in women, blood pressure of 130/85 mmHg or higher, fasting blood glucose level of 100 mg/dL (5.6 mg/L) or higher).

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Sedentary: Participants will remain seated for 7 h.

The sedentary condition will take place in a seated position. During the seated condition, volunteers will be seated at a typical desk chair at an appropriate height with hip and knee angles of ~90° and feet flat on the floor. The seating area will include a standard desk chair, a work desk, and the volunteers' personal laptops. Volunteers will be instructed prior to the visit to avoid behaviors such as fidgeting, excessive leg movements, and crossing their legs to minimize potential extraneous effects.
Ander: Sedentary Behaviour Intervention

Participants will remain seated for a total duration of 7 hours. During this period, they will be instructed to minimize excessive movement and will only be permitted to rise from the chair for voiding purposes.
Experimenteel: Breaking up sitting with aerobic exercise interruptions

The protocol that will interrupt sitting with AEI will involve cycle exercises performed at 50% of Wattmax for 2 minutes. The W and rpm levels corresponding to 50% of Wattmax will be determined using the values recorded during the determination of Wattmax.
Ander: Aerobic Exercise Intervention

In the aerobic exercise condition, participants will perform 2 minutes of moderate-intensity (%50 Wattmax) continuous cycling.
Experimenteel: Breaking up sitting with sprint exercise interruptions

The protocol that will interrupt sitting with SEI will involve cycle exercises performed at the maximum revolutions per minute achievable within 10 seconds. Immediately (2-3 seconds) before each SEI, volunteers will increase their pedal cadence to the maximum speed they can achieve, after which a pedal load will be applied to the bicycle ergometer and a sprint will be performed against the applied load for 10 seconds. During each sprint, the pedal load will be applied at %200 Wattmax level.
Ander: Sprint Exercise Intervention

In the sprint condition, participants will complete a 10-second sprint at %200 Wattmax level, as determined during the preliminary test.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Insulin
Tijdsspanne: 7 hour for each experimental condition

Postprandial insulin. Net incremental area under the curve and total area under the curve for each 7 h condition will be calculated for insulin.
7 hour for each experimental condition

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Glucose
Tijdsspanne: 7 hour for each experimental condition

Postprandial glucose. Net incremental area under the curve and total area under the curve for each 7 hour condition will be calculated for glucose.
7 hour for each experimental condition
CRP
Tijdsspanne: 7 hour

Postprandial CRP. Net incremental area under the curve and total area under the curve for each 7 h condition will be calculated for CRP.
7 hour
Substrate oxidation
Tijdsspanne: 0, 2th, 5th, 7th hours

Postprandial substrate oxidation. During each experimental visit, for 7 hours, volunteers' respiratory data will be collected using a direct calorimeter with canopy hood in lying position for 10 minutes at 0, 2th, 5th, and 7th hours. The volunteers' resting fat and carbohydrate oxidations will be determined from the obtained data.
0, 2th, 5th, 7th hours
Blood pressure
Tijdsspanne: 7 hour

Postprandial arterial blood pressure will be measured hourly for 7 h using an automatic blood pressure monitor with a cuff of appropriate size. The systolic and diastolic BP values measured will be recorded, and the mean arterial pressure will be calculated.
7 hour

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Hacettepe University

Onderzoekers

  • Hoofdonderzoeker: Şükran Nazan Koşar, Professor, Hacettepe University

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 september 2026

Primaire voltooiing (Geschat)

20 november 2026

Studie voltooiing (Geschat)

15 december 2026

Studieregistratiedata

Eerst ingediend

24 september 2025

Eerst ingediend dat voldeed aan de QC-criteria

13 november 2025

Eerst geplaatst (Werkelijk)

17 november 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

24 september 2026

Laatste update ingediend die voldeed aan QC-criteria

21 september 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • SBA 25/679

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

We do not plan to share IPD with other researchers due to privacy concerns and ethical restrictions outlined in the study's informed consent procedure.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren